


Application Ser. No.: 10/808,889
 Filing Date: March 25, 2004
 Examiner: Lee, Susannah E.

Amendment Pursuant to 37 C.F.R. § 1.121(c)

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (currently amended) A compound of formula (I)



wherein

A is aryl or heteroaryl;

R₁ is one or more groups selected from:

~~alkyl optionally substituted by one or more alkoxy, heteroalkyl, aryl, acyl, acyl derivative, halogen, amino, aminoalkyl, aminoalkylamino, hydroxy, hydroxyalkoxy, alkyl, arylalkyl, arylamino or aryloxy;~~

~~alkoxy optionally substituted by one or more alkyl, heteroalkyl, aryl, heteroaryl, alkoxyalkyl, hydroxyalkyl, amide, amino, acyl, acyl derivative, arylalkyl, perfluoroalkoxy, or alkylthio optionally substituted by amide, perfluoroalkylthio, amino, acyl, acyl derivative, alkyl, arylalkyl or aryl;~~

~~aryl or heteroaryl optionally substituted by one or more similar or different groups selected from alkyl, alkoxy, nitro, cyano, acyl derivative, perfluoroalkoxy, perfluoroalkyl, heteroaryl, aryloxy, halogen, hydroxyalkyl, amino, mono or dialkylamino, heterocyclylamino, arylamino, heteroarylamine, heterocycloalkyl, perfluoroalkylthio, or alkylthio optionally substituted by amino, acyl, acyl derivative, alkyl, arylalkyl or aryl;~~

~~halogen;~~

~~NH₂;~~

Application Ser. No.: 10/808,889

Filing Date: March 25, 2004

Examiner: Lee, Susannah E.

NH-alkyl or NH-cycloalkyl optionally substituted by acyl, acyl derivative, hydroxy, amino, alkoxy, heterocyclyl chosen from substituted or unsubstituted tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or azepanyl, or aryl; or 1-imidazolyl; or

SO_2Me ;

R_2 is:

-CO-alkyl or -CO-cycloalkyl wherein said -CO-alkyl or -CO-cycloalkyl is optionally substituted by one or more amino, acyl, acyl derivative, alkoxy, aryl, OH, aminoalkyl, aminoalkylamino, hydroxyalkoxy, alkyl, ~~heteroalkyl~~, arylalkyl, arylamino or aryloxy;

-CO-aralkyl optionally substituted by one or more similar or different groups selected from alkoxy, halogen, amino, acyl, acyl derivative, alkyl, hydroxyalkyl, mono or dialkylamino, ~~heterocyclylamino~~, arylamino, ~~heteroarylamine~~, ~~heteroaryl~~, nitro, ~~heterocycloalkyl~~, perfluoroalkyl, perfluoroalkoxy, perfluoroalkylthio, or alkylthio optionally substituted by amino, acyl, acyl derivative, alkyl, arylalkyl or aryl;

-CO-aryl optionally substituted by one or more similar or different groups selected from halogen, alkoxy, alkyl, hydroxyalkyl, alkylthio, amino, mono or dialkylamino, heterocyclylamino, arylamino, ~~heteroarylamine~~, ~~heteroaryl~~, nitro, ~~heterocycloalkyl~~, perfluoroalkyl, perfluoroalkoxy, perfluoroalkylthio, or acyl;

-CO-alkoxy optionally substituted by aryl, amino, acyl, acyl derivative, alkyl, arylalkyl or aryl;

-CO-amino, -CO-NHR₃, -CO-NR₃R₄ wherein R₃ and R₄ are selected independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, ~~heteroalkyl~~ heterocyclyl selected from pyrrolidinylalkyl, 2-oxo-pyrrolidinylalkyl, piperidinylalkyl, tetrahydropyranylalkyl or morpholinylalkyl, alkylheterocycloalkyl selected from 4-alkylpiperazinylalkyl or N-alkyl-pyrrolidinylalkyl, aryl, aralkyl, or together form an alkylene chain optionally containing one to 4 heteroatoms selected from azetidine, pyrrolidine or piperidine, and optionally

Application Ser. No.: 10/808,889

Filing Date: March 25, 2004

Examiner: Lee, Susannah E.

substituted by one or more amino, aminoalkyl, aminoalkylamino, hydroxy, alkoxy, hydroxyalkoxy, hydroxyalkylamino, halogen, acyl, acyl derivative, alkyl, ~~heteroalkyl~~, arylalkyl, arylamino, aryloxy or aryl; or

aryl or aralkyl optionally substituted by one or more similar or different groups selected from ~~heterocycloalkyl~~ heterocyclyl selected from morpholinyl or alkyl piperazinyl, alkyl, aryl, alkoxy, amino, fluoroalkyl, acyl derivative, halogen, hydroxyalkyl, mono or dialkylamino, ~~heterocyclylamine~~, arylamino, ~~heteroarylamine~~, heteroaryl selected from oxadiazolyl, nitro, ~~heterocycloalkyl~~, perfluoroalkyl, perfluoroalkoxy, perfluoroalkylthio, or alkylthio optionally substituted by amino, acyl, acyl derivative, alkyl, arylalkyl or aryl;

wherein when A is phenyl and R₁ is NH₂, NH-alkyl, NH-cycloalkyl or 1-imidazolyl, said phenyl is substituted at the 4-position with said R₁; and ~~when A is phenyl and R₁ is SO₂Me said phenyl is substituted at the 3-position with said R₁;~~

~~with the proviso that~~ when R₂ is -CO-alkoxy, R₁ is NH-cycloalkyl,

or a pharmaceutically acceptable salt ~~or a prodrug~~ thereof.

2. (original) The compound according to claim 1 wherein acyl is a carboxylic acid or a sulfonic acid and acyl derivative is an alkyl or carbamoyl ester.

3. (currently amended) A compound according to claim 2 wherein:

A is aryl ~~or heteroaryl~~;

R₁ is one or more groups selected from:

~~alkyl optionally substituted by alkoxy, heteroalkyl, aryl, acyl, acyl derivative, or halogen;~~

Application Ser. No.: 10/808,889
 Filing Date: March 25, 2004
 Examiner: Lee, Susannah E.

~~alkoxy optionally substituted by alkyl, heteroalkyl, aryl, heteroaryl,
 alkoxyalkyl, hydroxyalkyl, amide or perfluoroalkoxy, or alkylthio
 optionally substituted by an amide or perfluoroalkylthio;~~

~~aryl or heteroaryl optionally substituted by one or more alkyl, alkoxy,
 nitro, cyano, acyl derivative, perfluoroalkoxy, perfluoroalkyl, heteroaryl or
 aryloxy;~~

~~halogen;~~

~~NH₂;~~

~~NH-alkyl or NH-cycloalkyl optionally substituted by acyl, acyl derivative,
 hydroxy, amino, alkoxy, heterocyclyl chosen from substituted or
 unsubstituted tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, 2-oxo-
 pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or azepanyl, or aryl; or~~

~~1-imidazolyl; or~~

~~SO₃Me;~~

R₂ is:

~~-CO-alkyl or -CO-cycloalkyl wherein said -CO-alkyl or -CO-cycloalkyl is
 optionally substituted by amino, acyl, acyl derivative, alkoxy, aryl or OH;~~

~~-CO-aralkyl optionally substituted by alkoxy, halogen, amino, acyl or acyl
 derivative;~~

~~-CO-aryl optionally substituted by halogen, alkoxy, alkyl, hydroxyalkyl,
 alkylthio, amino, mono or dialkylamino, nitro, perfluoroalkyl,
 perfluoroalkoxy, perfluoroalkylthio, or acyl;~~

~~-CO-alkoxy optionally substituted by aryl;~~

~~-CO-amino, -CO-NHR₃, -CO-NR₃R₄ wherein R₃ and R₄ are selected
 independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl,
 fluoroalkyl, alkynyl, ~~heteroalkyl~~ heterocyclyl selected from~~

Application Ser. No.: 10/808,889
Filing Date: March 25, 2004
Examiner: Lee, Susannah E.

pyrrolidinylalkyl, 2-oxo-pyrrolidinylalkyl, piperidinylalkyl,
tetrahydropyranylalkyl or morpholinylalkyl, alkylheterocycloalkyl selected
from 4-alkylpiperazinylalkyl or N-alkyl-pyrrolidinylalkyl, aryl, aralkyl or
together form an alkylene chain optionally containing one to 4 heteroatoms
selected from azetidine, pyrrolidine or piperidine; or
aryl or aralkyl optionally substituted by ~~heterocycloalkyl~~ heterocyclyl
selected from morpholinyl or alkyl piperazinyl, alkyl, aryl, alkoxy, amino,
fluoroalkyl, acyl derivative, or halogen.

4. (currently amended) The compound according to claim 3 wherein A is phenyl-,
~~thiophenyl, isoxazolyl, oxazolyl, pyrazolyl, furanyl or pyridinyl.~~
5. (canceled).
6. (currently amended) The compound according to ~~claim 5~~ claim 4 wherein R₁ is NH-
cycloalkyl and R₂ is -CO-alkoxy.
7. (original) The compound according to claim 6 wherein the compound is
methyl-5-(4-cyclopentylaminophenylsulfonyloxy) benzimidazole-2-carbamate.
8. (currently amended) The compound according to ~~claim 5~~ claim 4 wherein R₁ is 1-
imidazolyl or cyclopentylamino and R₂ is -CO-alkyl optionally substituted by amino,
acyl, acyl derivative, alkoxy, aryl or OH.
9. (original) The compound according to claim 8 wherein the compound is selected from
the group consisting of:
N-[5-(4-imidazol-1-yl-benzenesulfonyloxy)-1H-benzoimidazol-2-yl]-succinamic acid
methyl ester,

Application Ser. No.: 10/808,889
Filing Date: March 25, 2004
Examiner: Lee, Susannah E.

N-[5-(4-cyclopentylamino-benzenesulfonyloxy)-1H-benzoimidazol-2-yl]-succinamic acid methyl ester,
4-[5-(4-cyclopentylamino-benzenesulfonyloxy)-1H-benzoimidazol-2-ylcarbamoyl]-butyric acid methyl ester, and
4-cyclopentylamino-benzenesulfonic acid 2-(2-methoxy-acetylamino)-1H-benzoimidazol-5-yl ester.

10. (currently amended) The compound according to ~~claim 5~~ claim 4 wherein R₁ is ~~alkoxy~~, 1-imidazolyl, or NH-alkyl or NH-cycloalkyl optionally substituted by acyl, acyl derivative, hydroxy, amino, alkoxy, heterocyclyl chosen from substituted or unsubstituted tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or azepanyl or aryl and R₂ is -CO-amino, -CO-NHR₃, -CO-NR₃R₄ wherein R₃ and R₄ are selected independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, ~~heteroalkyl~~ heterocyclyl selected from pyrrolidinylalkyl, 2-oxo-pyrrolidinylalkyl, piperidinylalkyl, tetrahydropyranylalkyl or morpholinylalkyl, alkylheterocycloalkyl selected from 4-alkylpiperazinylalkyl or N-alkyl-pyrrolidinylalkyl, aryl, aralkyl or together form an alkylene chain optionally containing one to 4 heteroatoms selected from azetidine, pyrrolidine or piperidine.

11. (currently amended) The compound according to claim 10 selected from the group consisting of:

N-[5-(4-[imidazolyl]-phenylsulfonyloxy)-1H-benzimidazole-2-yl]-methylurea,

N-[5-(4-cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-methylurea,

N-[5-(4-cyclopentylaminophenylsulfonyloxy)-1H-benzimidazole-2-yl]-dimethylurea,

4-cyclopentylamino-benzenesulfonic acid 2-(3-isopropyl-ureido)-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889

Filing Date: March 25, 2004

Examiner: Lee, Susannah E.

4-cyclopentylamino-benzenesulfonic acid 2-(3-butyl-ureido)-1H-benzoimidazol-5-yl ester,

4-imidazol-1-yl-benzenesulfonic acid 2-[3-(2-fluoro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-fluoro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(3-methoxy-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(4-methoxy-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(4-chloro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(3-fluoro-benzyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(3-chloro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-(3-isobutyl-ureido)-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-dimethylamino-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,

4-cyclopentylamino-benzenesulfonic acid 2-(3-ethyl-ureido)-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889
Filing Date: March 25, 2004
Examiner: Lee, Susannah E.

- 4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-methoxy-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,
- 4-cyclopentylamino-benzenesulfonic acid 2-[3-(4-dimethylamino-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,
- 4-cyclopentylamino-benzenesulfonic acid 2-(3-tert-butyl-ureido)-1H-benzoimidazol-5-yl ester,
- 4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-(3-methyl-ureido)-1H-benzoimidazol-5-yl ester,
- 4-imidazol-1-yl-benzenesulfonic acid 2-(3-phenyl-ureido)-1H-benzoimidazol-5-yl ester,
- 4-imidazol-1-yl-benzenesulfonic acid 2-[3-(3-fluoro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,
- 4-imidazol-1-yl-benzenesulfonic acid 2-[3-(2-hydroxy-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,
- 4-imidazol-1-yl-benzenesulfonic acid 2-[3-(4-fluoro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,
- 4-imidazol-1-yl-benzenesulfonic acid 2-[3-(2-chloro-benzyl)-ureido]-1H-benzoimidazol-5-yl ester,
- 4-imidazol-1-yl-benzenesulfonic acid 2-[3-(2-fluoro-benzyl)-ureido]-1H-benzoimidazol-5-yl ester,
- 4-imidazol-1-yl-benzenesulfonic acid 2-[(azetidine-1-carbonyl)-amino]-1H-benzoimidazol-5-yl ester,
- 4-imidazol-1-yl-benzenesulfonic acid 2-(3-benzyl-ureido)-1H-benzoimidazol-5-yl ester,
- 4-cyclopentylamino-benzenesulfonic acid 2-(3-phenyl-ureido)-1H-benzoimidazol-5-yl ester,
- 4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-hydroxy-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,
- 4-cyclopentylamino-benzenesulfonic acid 2-[3-(4-fluoro-phenyl)-ureido]-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889
Filing Date: March 25, 2004
Examiner: Lee, Susannah E.

4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-chloro-benzyl)-ureido]-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-fluoro-benzyl)-ureido]-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-[(azetidine-1-carbonyl)-amino]-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-(3-benzyl-ureido)-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-[3-(3-hydroxy-propyl)-ureido]-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-[3-(1,1-dimethyl-propyl)-ureido]-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-[3-(4-hydroxy-butyl)-ureido]-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-[3-(2-hydroxy-1-methyl-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,
4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-[3-(2-hydroxy-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,
4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-[3-(3-hydroxy-propyl)-ureido]-1H-benzoimidazol-5-yl ester,
4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-[3-(4-hydroxy-butyl)-ureido]-1H-benzoimidazol-5-yl ester,
4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-[3-(2-methoxy-1-methyl-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,
4-[(tetrahydro-furan-2-ylmethyl)-amino]-benzenesulfonic acid 2-(3-ethyl-ureido)-1H-benzoimidazol-5-yl ester.
4-(2-methoxy-ethylamino)-benzenesulfonic acid 2-[3-(2-ethyl)-ureido]-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889
Filing Date: March 25, 2004
Examiner: Lee, Susannah E.

4-(2-hydroxy-1-methyl-ethylamino)-benzenesulfonic acid 2-[3-(2-methoxy-ethyl)-ureido]-1H-benzimidazol-5-yl ester,
4-(2-hydroxy-1-methyl-ethylamino)-benzenesulfonic acid 2-[3-(2-ethyl)-ureido]-1H-benzimidazol-5-yl ester,
~~4-benzoyloxy-benzenesulfonic acid 2-[3-(2-methoxy-ethyl)-ureido]-1H-benzimidazol-5-yl ester,~~
4-(2-morpholin-4-yl-ethylamino)-benzenesulfonic acid 2-[3-(2-methoxy-ethyl)-ureido]-1H-benzimidazol-5-yl ester,
4-[(piperidin-4-ylmethyl)-amino]-benzenesulfonic acid 2-[3-(2-methoxy-ethyl)-ureido]-1H-benzimidazol-5-yl ester, and
4-(2-hydroxy-3-methoxy-propylamino)-benzenesulfonic acid 2-[3-(2-hydroxy-3-methoxy-propyl)-ureido]-3H-benzimidazol-5-yl ester.

12. (currently amended) The compound according to ~~claim 5~~ claim 4 wherein R₂ is -CO-cycloalkyl.

13. (original) The compound according to claim 12 wherein R₂ is -CO-cyclopropyl.

14. (currently amended) The compound according to claim 13 selected from the group consisting of:

4-benzylamino-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzimidazol-5-yl ester,
4-methylamino-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzimidazol-5-yl ester,
4-(2-hydroxy-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzimidazol-5-yl ester,
4-(3-hydroxy-propylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzimidazol-5-yl ester,

Application Ser. No.: 10/808,889
Filing Date: March 25, 2004
Examiner: Lee, Susannah E.

4-(4-hydroxy-butylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(2-methoxy-1-methyl-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(2-pyrrolidin-1-yl-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(1-hydroxymethyl-propylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(2-hydroxy-1-methyl-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(2-piperidin-1-yl-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(3-pyrrolidin-1-yl-propylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(3-hydroxy-2,2-dimethyl-propylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-[3-(4-methyl-piperazin-1-yl)-propylamino]-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(2-methoxy-benzylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(2-diethylamino-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(1S-hydroxymethyl-propylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(2-morpholin-4-yl-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
4-(1-aza-bicyclo[2.2.2]oct-3-ylamino)-benzenesulfonic acid 2-(cyclopropane-carbonyl-amino)-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889
 Filing Date: March 25, 2004
 Examiner: Lee, Susannah E.

4-(2R-carbamoyl-pyrrolidin-1-yl)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
 4-(2-piperazin-1-yl-ethylamino)-benzene-sulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
 4-(2-carbamoyl-cyclohexylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
 4-(2-acetyl-amino-ethylamino)-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
 4-[2-(2-amino-ethylamino)-ethylamino]-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
 4-[2-(1H-imidazol-4-yl)-ethylamino]-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester,
 4-[(pyridin-2-ylmethyl)-amino]-benzenesulfonic acid 2-(cyclopropane-carbonyl-amino)-1H-benzoimidazol-5-yl ester,
 4-cyclobutylamino-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester, and
 4-[2-(2-hydroxy-ethoxy)-ethylamino]-benzenesulfonic acid 2-(cyclopropanecarbonyl-amino)-1H-benzoimidazol-5-yl ester.

15. (currently amended) The compound according to ~~claim 5~~ claim 4 wherein R₁ is cyclopentylamino and R₂ is aryl or aralkyl optionally substituted by heterocycloalkyl, ~~heterocyclyl selected from morpholinyl or methylpiperazinyl~~, alkyl, aryl, alkoxy, amino, ~~fluoroalkyl~~ fluoroalkyl, acyl derivative, or halogen.

16. (original) The compound according to claim 15 selected from the group consisting of:

4-cyclopentylamino-benzenesulfonic acid 2-(3,4-dimethoxy-phenylamino)-1H-benzoimidazol-5-yl ester,
 4-cyclopentylamino-benzenesulfonic acid 2-phenylamino-1H-benzoimidazol-5-yl ester,

Application Ser. No.: 10/808,889
Filing Date: March 25, 2004
Examiner: Lee, Susannah E.

4-cyclopentylamino-benzenesulfonic acid 2-(4-morpholin-4-yl-phenylamino)-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-(3,5-dimethyl-phenylamino)-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-(4-methoxy-phenylamino)-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-(4-dimethylamino-phenylamino)-1H-benzoimidazol-5-yl ester,
4-cyclopentylamino-benzenesulfonic acid 2-(3-methoxy-5-trifluoromethyl-phenylamino)-1H-benzoimidazol-5-yl ester,
3-[5-(4-cyclopentylamino-benzenesulfonyloxy) -1H-benzoimidazol-2-ylamino]-benzoic acid ethyl ester, and
4-cyclopentylamino-benzenesulfonic acid 2-[(4-(4-methyl-piperazin-1-yl)-phenylamino)-1H-benzoimidazol-5-yl ester.

17. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 and one or more pharmaceutically acceptable adjuvants or diluents.

18. (currently amended) A method of treating a patient for cancer selected from the group consisting of breast, ovarian, bladder, esophageal, lung and lymphoma, comprising administering to said patient a therapeutically effective amount of a compound of formula (I) according to claim 1.